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Abstract
Objective: To investigate whether Adjunctive PD-1 inhibitors have improved clinical outcomes
compared to chemotherapy alone in platinum-pretreated and platinum-naive recurrent or
metastatic nasopharyngeal carcinoma (R/M NPCA).
Methods: The study involved a literature search from PubMed, Cochrane CENTRAL, and
Google Scholar for randomized clinical trials (RCTs) on the use of PD-1 inhibitors versus
chemotherapy alone in patients with R/M NPCA. Bias was assessed using Cochrane
collaboration’s risk of bias tool. Overall Survival (OS) was examined as the primary endpoint.
Secondary endpoints were Progression-Free Survival (PFS), Objective Response Rate, Disease
Control Rate (DCR), Duration of Response, and Serious/Grade ⩾3 Adverse Events. Outcomes
were measured with either Mean Difference, Risk ratio (RR), or Hazard ratios (HRs) at 95%
confidence interval.
Results: Four RCTs were included in the meta-analysis and systematic review. OS for the
monotherapy subgroup was a HR of 0.87 [0.67, 1.13] (p = 0.30) while the combination subgroup
had 0.64 [0.45, 0.90] (p = 0.01). The monotherapy subgroup exhibited significantly worse
outcomes in PFS (HR 1.31 [1.01, 1.68]) (p = 0.04) and DCR (RR 1.52 [1.12, 2.05]) (p = 0.007) but
no significant difference in other outcomes. For combination therapy, a statistically significant
benefit can be seen in all outcomes except DCR (RR 0.62 [0.38, 1.01]) (p = 0.06) which was a
non-significant benefit favoring PD-1 inhibitors.
Conclusion: Combination PD-1 inhibitor + chemotherapy followed by maintenance PD-1
inhibitor therapy is superior to chemotherapy alone in the first-line treatment of R/M NPCA,
implying a potential benefit with the use of PD-1 inhibitors + chemotherapy with maintenance
PD-1 inhibitors as first-line in R/M NPCA compared to standard chemotherapy alone.
Keywords: anti-PD-1, checkpoint inhibitor, chemotherapy, metastasis, nasopharyngeal
carcinoma
Received: 7 August 2022; revised manuscript accepted: 19 October 2022.

Introduction
Nasopharyngeal carcinoma (NPCA) is a malignant neoplasm developing from the epithelial lining of the nasopharynx and commonly associated
with Epstein-Barr virus (EBV) infection. It is
notable as one of the malignancies with a known
ethnic predisposition, arising primarily from

people of Chinese descent. Aligning with this, its
worldwide distribution in 2018 shows China as
occupying an age-standardized incidence rate of
60,558 (47.7%) cases out of 100,000.1 This was
closely followed by Southeast Asia (SEA) with an
age-standardized incidence rate of 29,317
(29.3%) cases out of 100,000.1 This could easily
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be explained by the proximity of SEA to China,
leading to a likely Chinese genetic diaspora onto
these regions.
It is speculated that the Human Leukocyte Antigen
(HLA) gene and the Cytochrome P450 2A6
(CYP2A6) genes are likely culprits for the predisposition of Chinese individuals and Southeast
Asians to developing NPCA. The HLA class II
gene, HLA-A*0207, was found to be carried by
south Chinese populations at a significantly higher
rate than in Caucasians.2,3 This relates to EBV as
HLA class II receptors are utilized for viral penetration after the viral glycoprotein, gp42, binds to
HLA class II on the cell surface of B cells.4
CYP2A6 polymorphisms were similarly found to
be associated with NPCA according to a case-control study done in the National Cancer Institute of
Thailand. CYP2A6 polymorphisms cause carcinogen accumulation by activating aflatoxins and
nitrosamines into their ultimate form carcinogens
that ultimately lead to DNA damage. It is also
involved with the metabolization of nicotine, possibly predisposing to a cyclical behavior of addiction that could further expose an individual to
nitrosamines from smoking.5
NPCA is highly sensitive to chemoradiation which
changed its 5 years overall survival (OS) from 25
to 40% to approximately 70% in recent years.6
For those with untreated recurrent or metastatic
(R/M) NPCA, current studies support the efficacy
of platinum-based doublet chemotherapy as the
recommended treatment.7–9 However, current
standard of therapy often leads to a median survival rate of no more than 1 year at most in those
with distant metastases.10,11 Thus, studies exploring alternative treatment modalities for a possibility of providing better outcomes are warranted.
Programmed cell death protein 1 (PD-1) inhibitors have been extensively studied in other forms
of malignant neoplasms, including other head
and neck cancers (HNCs), showing very optimistic outcomes in their use. The phase 3 trial from
Ferris et al.12 on nivolumab use in recurrent and
metastatic HNC, except NPCA, showed that OS
benefit was significantly longer with nivolumab
than with standard therapy [hazard ratio (HR),
0.70; 97.73% confidence interval (CI), 0.51–
0.96; p = 0.01].12 Similarly, the phase 3 study by
Cohen et al.13 on an identical population showed
a significant benefit with pembrolizumab over
standard therapy in OS [HR, 0.80 (0.65–0.98);
p = 0.016].13 PD-1 inhibitors are currently
2
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accepted as a standard of treatment in non-small
cell lung cancer (NSCLC) with no driver mutations expressing PD-L1 levels of ⩾50% while
becoming an essential component of therapy
alongside chemotherapy in those with PD-L1 levels of <50%.14
PD-1 is a surface receptor that has an important
part in regulating t-cell function. It is expressed in
active T cells, B cells, activated monocytes, and
dendritic cells and acts as a negative regulator
that helps induce self-tolerance.15 When stimulated, PD-1 inhibits early activation events of
involved cells in the presence of the co-stimulatory signals: CD28 and IL-2. Both CD28 and
IL-2 promote an antiapoptotic effect as it affects
PD-1. Consequently, withdrawal of these
cytokines leads to cell death.15 With regards to
cancers, the most important ligand for PD-1 is
the Programmed death-ligand 1 (PD-L1) protein. PD-L1 is usually expressed by tumor-associated antigen presenting cells including dendritic
cells, macrophages, fibroblasts, and T cells.16 It is
positively regulated by interferon-γ which is
induced in effector t-cells by the presence of
tumor cells.16 When bound to PD-1, PD-L1
inhibits the process of apoptosis that leads to
uncontrolled cell growth. Hence the reason why
drugs that inhibit the binding of PD-1 to PD-L1
would negatively impact the proliferation of
tumor cells. This relationship between PD-1,
PD-L1, their chemical regulators, and the association of EBV infection with an increased PD-L1
expression all help explain the role of PD-1/
PD-L1 interaction in the growth of NPCA and
the rationale behind the use of PD-1 inhibitors as
a treatment for malignancy.17
A meta-analysis would benefit the limited trials
currently available by increasing the total power
of the studies through pooling together and synthesizing their results. Because of this, we have
decided to investigate the efficacy and safety of
PD-1 inhibitors as a therapeutic approach for
R/M NPCA by doing a meta-analysis.
Methodology
Eligibility criteria
Randomized controlled trials comparing the use
of PD-1 inhibitors, with or without chemotherapy, compared to chemotherapy alone in R/M
NPCA among adult patients were included in the
study. A control group composed of patients
journals.sagepub.com/home/tam
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Google Scholar were used as secondary database.
Specific search keywords and MeSH terms used
were: ‘nasopharyngeal carcinoma OR npca’,
‘recurrent OR metastatic’, ‘PD-1’, ‘camrelizumab
OR toripalimab OR pembrolizumab OR spartalizumab OR nivolumab OR checkpoint inhibitor
OR anti PD’, ‘chemotherapy’ and ‘clinical trial OR
RCT OR randomized clinical trial OR randomized
controlled trial OR randomized control trial’ to
search for relevant studies. The PICO question
was ‘Are PD-1 inhibitors, with or without chemotherapy, superior to standard chemotherapy regimens alone in patients with metastatic or recurrent
NPCA?’. References within the primary selected
studies reviewed in the full text were screened as
well as gray literature. Last search was done on 20
September 2022; 2:30:00 pm (Figure 1).

Figure 1. Flow diagram of literature search and
study selection based on preferred reporting items
for systematic reviews and meta-analyses protocols
(PRISMA-P) recommendation.
NPCA, nasopharyngeal carcinoma.

diagnosed with NPCA and treated with chemotherapy must be present. The studies included
must have a sample population of only adult
patients with histologic diagnosis of NPCA.
Retrospective studies, case reports, case series,
single-armed, and non-randomized studies were
excluded from the meta-analysis. Pediatric
patients were also excluded given innate differences in physiology. Furthermore, the studies
included must also look at the OS, ProgressionFree Survival (PFS), Objective Response Rate
(ORR), Disease Control Rate (DCR), Duration
of Response (DOR), and must provide either the
actual counts or HRs. Adverse Effects (AEs) were
also included but must be classified as Serious or
Grade ⩾3.
Search methods for identification of studies
The search was done according to the PRISMA-P
guidelines and wasn’t restricted by language, date,
publication status, or any other trial characteristics. The following electronic databases were utilized for the search: PubMed Central as the
primary database. Cochrane CENTRAL and
journals.sagepub.com/home/tam

Selection of studies
Two authors (ETP and JAC) independently
screened each title and abstract of each study. For
studies with uncertainties evaluated in the title and
abstract, the full text was reviewed. All screened
studies were assessed for inclusion in accordance
with the eligibility criteria. Disagreements were
resolved by discussions between the two screening
authors. A third author (SC) was consulted when
a consensus could not be met.
Data extraction
From the included studies, data were independently extracted such as the type of study design,
year of publication, country of origin, sample size
and their baseline characteristics, inclusion and
exclusion criteria, treatment arms, dosage, length
of follow-up, and reported outcomes. From this,
the eligibility criteria as well as the nature of intervention were derived.
Outcomes
The primary outcome measure is the OS calculated from both arms and measured in months.
We define the OS as the time from randomization
until death from any cause.18 Secondary outcomes
include PFS, ORR, DCR, DOR, and Serious or
Grade ⩾3 drug-related AEs. ORR is computed by
adding complete response and partial response.
DCR used the percentage of complete response,
partial response, and stable disease. HR was used
for OS and PFS measurement. Risk ratio (RR)
was used for ORR, DCR, and AEs. Mean difference (MD) was used to measure DOR. All pooled
3
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Figure 2. Risk of bias summary; green: low risk; red: high risk; other bias: presence of sponsorship bias due
to financial support from either Merck Sharp & Dohme Corp, Novartis Pharmaceuticals Corporation, Shanghai
Junshi Biosciences, or Jiangsu Hengrui Pharmaceuticals and Junshippharma.

outcomes were assessed with 95% CIs with a random-effects model.
Risk of bias
Two authors (ETP and JAC) independently
assessed the risk of systematic errors (bias) in the
included studies using the Cochrane collaboration’s risk of bias tool for randomized studies.19
The criteria to appraise the studies included: random sequence generation, allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases
were assessed (Figure 2).
Data synthesis
Review Manager version 5.4.1 was used for data
synthesis of OS, PFS, ORR, DCR, DOR, and
4

Serious or Grade ⩾3 drug-related AEs. Data types
for OS and PFS utilized an inverse-variance model
with HR as the measure of association. Meanwhile,
a dichotomous analysis utilizing RR was used for
ORR, DCR, and AEs. However, plotting of results
for ORR and DCR was analyzed through nonevents analysis to assess the amount of nonresponders while events analysis was used for AE.
DOR was analyzed with a continuous data model
using the mean in months to plot the MD between
study arms. All outcomes were assessed for significance using p-values and outliers with the z-score.
Where appropriate, the median was used as a surrogate for the mean by conversion using the methods described by Hozo et al. (2005).20 The
standard of error for plotting HR was computed
with the formula ln(HR)/z score or [ln(upper limit
of CI) − ln(lower limit of CI)]/3.92.19 For studies
with no reported HR, HR was estimated using the
hazard rate obtained with the formula h = ln(2)/
journals.sagepub.com/home/tam
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Mean Survival Time.21 Random effects were used
for all data synthesized.
Assessment of heterogeneity
Heterogeneity was tested by df, I2, Chi2, and
Tau2. I2 was interpreted as follows: 0–40%: might
not be important; 30–60%: may represent moderate heterogeneity; 50–90%: may represent substantial heterogeneity; 75–100%: considerable
heterogeneity.19 Subgroup analysis was used in an
attempt to control for any heterogeneity.
Results
Search results
Around 4 out of 420 studies were included into
the meta-analysis. Included studies were required
to be two-armed randomized clinical trials (RCTs)
measuring the difference between PD-1 inhibitors
versus standard chemotherapy on an adult NPCA
population. Retrospective studies, case reports or
case series, including studies in pediatric patients,
were excluded. Single-armed and non-randomized studies were also excluded from the data
synthesis. PubMed, Cochrane CENTRAL, and
Google Scholar were used to search for eligible
studies. Studies must have also measured OS,
PFS, ORR, DCR, DOR, and Serious or Grade
⩾3 drug-related AEs as outcomes to be included
into the meta-analysis. A flow-diagram of the
search strategy can be seen in Figure 1.
All included studies were RCTs comparing the
efficacy and safety of PD-1 inhibitors versus
chemotherapy published in 2021. The studies by
Chan et al.,22 Yang et al.,23 and Mai et al.24 were
all Phase III RCTs whereas the study by Even
et al.25 was a Phase II RCT. All three were published as original articles with the exception of
Chan et al.22 which was published as an abstract.
A total of 907 participants were randomized and
analyzed according to subgroups with a total of
355 in the monotherapy subgroup and 552 in the
combination subgroup. In the analysis, certain
distinctions were made for subgroup pairings.
The studies by Chan et al. and Even et al. were
categorized as the monotherapy subgroup while
the studies by Yang et al. and Mai et al. were categorized as the combination therapy subgroup.
Characteristics shared within the monotherapy
subgroup were the use of single-agent PD-1
inhibitors, an open-label study design, and a population of platinum-pretreated R/M NPCA.
journals.sagepub.com/home/tam

Whereas those in the combination subgroup were
given combined PD-1 inhibitor + chemotherapy,
had a double-blinded design, and a population of
R/M NPCA undergoing first-line treatment. A
cumulative subgroup analysis was not done due
to inherent differences in their populations,
namely whether patients were platinum pretreated or undergoing first-line therapy. A more
comprehensive descriptive analysis of the individual studies can be seen in Table 1.
Objective response rate
PD-1 monotherapy subgroup analysis showed an
RR of 1.12 [0.90, 1.37] (p = 0.31). The combination subgroup showed an RR of 0.67 [0.49, 0.91]
(p = 0.01) (Supplemental Figure 1).
Disease control rate
PD-1 monotherapy subgroup showed an RR of
1.52 [1.12, 2.05] (p = 0.007). Combination therapy showed an RR of 0.62 [0.38, 1.01] (p = 0.06)
(Supplemental Figure 2).
Duration of response
PD-1 monotherapy showed an MD of 2.43
[−2.86, 7.73] (p = 0.37), revealing a non-significant benefit. The combination therapy subgroup
showed a statistically significant benefit with an
MD of 3.71 [2.35, 5.06] (p < 0.001)
(Supplemental Figure 3).
Safety
The monotherapy subgroup revealed an RR of
0.64 [0.30, 1.39] (p = 0.26) for Total Adverse
Events (Supplemental Figure 4) While the combination subgroup showed an RR of 1.01 [0.96,
1.07] (p = 0.65) for Total Adverse Events
(Supplemental Figure 5). Analysis of specific AEs
showed no significant difference between treatment and control arms with the exceptions of
monotherapy anemia (RR 0.13 [0.02, 0.71];
p = 0.02), monotherapy neutropenia (RR 0.08
[0.01, 1.01]; p = 0.05), and monotherapy diarrhea
(RR 0.10 [0.01, 0.83]; p = 0.03). Information on
the AEs included in the data synthesis can be seen
on Supplemental Table 1.
Progression-free survival
The PFS for PD-1 monotherapy showed an HR
of 1.31 [1.01, 1.68] (p = 0.04). Whereas, the
5
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OS, median (95% CI), mo
Pembrolizumab:17.2 (11.7–22.9)
Standard treatment: 15.3 (10.9–18.1)
Hazard ratio (HR) (95% CI): 0.90
(0.67–1.19)
p = 0.2262
PFS, median (95% CI), mo
Pembrolizumab: 4.1 (2.1–5.6)
Standard Treatment: 5.5 (4.0–8.1)
HR (95% CI): 1.28 (0.94–1.75)
p = 0.9419
ORR, % (95% CI)
Pembrolizumab: 21.4% (14.3–29.9)
Standard treatment: 23.3% (15.9–
32.0)
p = 0.63479
DCR (CR + PR + SD), % (95% CI)
Pembrolizumab: 50.4% (41.0–59.8)
Standard treatment: 63.8% (54.4–
72.5)
p = 0.0414*
DOR, median (range), mo
Pembrolizumab:12.0 (1.7+ to 49.7+)
Standard treatment: 13.1 (2.6–49.3+)
p = 0.7389*
OS, median (95% CI), mo
Spartalizumab: 25.2 months (95% CI,
13.1–NE)
Chemotherapy: 15.5 months (95% CI,
8.3–21.3)
HR = 0.615*
p = 0.138
PFS, median (95% CI), mo
Spartalizumab: 1.9 months (95% CI,
1.8–3.6)
Chemotherapy: 6.6 months (95% CI,
3.7–9.3)
HR 1.36 (95% CI, 0.87–2.12)
One-sided stratified log-rank test
p = 0.915
ORR, % (95% CI)
Spartalizumab: 17.1% (95% CI,
9.7–27.0)
Chemotherapy: 35.0% (95% CI,
20.6–51.7)
p = 0.0272*

Total n = 233
Intervention: Pembrolizumab
(n = 117); pembrolizumab 200 mg
intravenously (IV) on day 1 of
each 3-week cycle (Q3W) until
progressive disease (PD) or
unacceptable toxicity for a
maximum of up to 35 cycles (up
to approximately 2 years).
Control: Standard doses of
chemo (n = 116); capecitabine
1000 mg/m2 orally (PO)
twice each day (BID) on Days
1–14 of each 3-week cycle, or
gemcitabine 1250 mg/m2 IV on
Days 1 and 8 of each 3-week
cycle, or docetaxel 75 mg/
m2 IV on day 1 of each 3-week
cycle until PD or unacceptable
toxicity.
Follow-up: up to 53 months

Total n = 122
Intervention: Spartalizumab
(n = 82); Spartalizumab was
administered IV at 400 mg
every 4 weeks in 28-day cycles
until unacceptable toxicity, PD
per irRC, and/or treatment
discontinuation due to patient/
physician’s decision
Control: Investigator’s
choice chemotherapy (n = 40);
chemotherapy per investigator’s
choice was dosed according to
the drug label(s)
Follow-up: From randomization
up to maximum of 3.3 years

Age, years (mean SD)
Pembrolizumab: 50.6
(12.7)
Standard treatment:
53.1 (11.2)
Sex
Male: 82.8%
Female: 17.2%
Race
Asian: 95.3%
Black: 0.4%
White: 4.3%
PD-L1 CPS ⩾ 1.
Pembrolizumab:
87 (74.4%)
Chemotherapy: 73
(62.9%)

Age, years (range)
Spartalizumab: 51
(21–74)
Chemotherapy: 50
(26–78)
Sex
Male: 82.8%
Female: 17.2%
Race
Asian: 87.7%
White: 11.5%
Black: 0.8%
PD-L1 expression,
percent positive tumor
cells
Spartalizumab: 78
(95.1%)
Chemotherapy: 38
(95.0%)

Previously treated in the
recurrent/metastatic
setting with any one
of the three standard
therapies
Immunodeficiency
Prior anti-cancer
monoclonal antibody
(mAb) therapy
Active autoimmune
disease
Active infection
Human
immunodeficiency virus
(HIV) hepatitis B or C
positive
Pregnant, breastfeeding,
or expecting to conceive
or father children
Live vaccine within
30 days of planned start
of study drug

Severe hypersensitivity
reactions to other mAbs
Autoimmune disease.
Active HBV or HCV
infections requiring
therapy
Prior PD-1- or PD-L1directed therapy
Systemic treatment with
any immunosuppressive
Use of any vaccines
within 4 weeks of
initiation of study
treatment.

Histologically confirmed
non-keratinizing
differentiated NPCA or
undifferentiated NPCA
Metastatic disease or
incurable locally recurrent
disease
Treatment with prior
platinum therapy
Tumor tissue available for
PD-L1 testing
Measurable disease based
on RECIST 1.1
ECOG performance status
of 0 or 1
Adequate organ function
Must be willing to use
contraception
Life expectancy of at least
3 months

Histologically documented
non-keratinizing locally
advanced R/M NPCA
Resistant to platinumbased chemotherapy
May have received up to two
prior systemic therapies
At least one measurable
lesion (as per RECIST v1.1)
Must be willing to undergo
testing for HIV
If HIV+ positive, eligible
if: CD4+ count ⩾300/μL;
undetectable viral load; on
HAART

Chan et al.
858O Results of
KEYNOTE-122: A phase III
study of pembrolizumab
(pembro) monotherapy
versus chemotherapy
(chemo) for platinumpretreated, recurrent
or metastatic (R/M)
nasopharyngeal
carcinoma (NPCA)
2021
Phase III, open-labeled,
RCT
International multicenter
cohort from Australia,
Canada, Hong Kong,
Korea, Malaysia,
Philippines, Singapore,
Taiwan, Thailand, United
States

Even et al.
Phase II, randomized
Study of spartalizumab
(PDR001), an antiPD-1 antibody, versus
chemotherapy in patients
with R/M nasopharyngeal
cancer
2021
Phase II, open-label, RCT
International Multicenter
Cohort from US, China,
France, Hong Kong,
Singapore, Taiwan,
Thailand

(Continued)

Outcomes

Treatment arms, dosage and
length of follow-up

Baseline
characteristics

Exclusion criteria

Inclusion criteria

First author, title, year,
design, location

Table 1. Summary of study characteristics.
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Inclusion criteria

Age ⩾18 and ⩽75 years
Histological/cytological
confirmation of NPCA
Primarily metastatic (stage
IVB) or recurrent NPCA
At least one measurable
lesion according to RECIST
version 1.1
Life expectancy ⩾3 months

First author, title, year,
design, location

Mai et al.
Toripalimab or placebo
plus chemotherapy as
first-line treatment in
advanced nasopharyngeal
carcinoma: a multicenter
randomized phase 3 trial
2021
Phase III, double-blinded,
RCT
International Multicenter
Cohort in China, Taiwan,
and Singapore

Table 1. (Continued)
Treatment arms, dosage and
length of follow-up

Total n = 289
Intervention: Toripalimab + GP
(n = 146); means of 11.5 cycles,
38.31 weeks for toripalimab; 5.1
cycles, 17.16 weeks for cisplatin;
5.3 cycles, 18.62 weeks for
gemcitabine
Control: Placebo + GP
(n = 143); means of 10.7 cycles,
35.5 weeks for placebo; 5.3
cycles, 17.22 weeks for cisplatin;
5.1 cycles, 18.59 weeks for
gemcitabine
Follow-up: Up to 24 months

Baseline
characteristics

Age, years (median,
IQR)
Toripalimab + GP: 46
(19–72)
Placebo + GP: 51
(21–72)
Sex
Male: 83.04%
Female: 16.96%
Ethnicity
Asian: 100%
PDL1 positive
Toripalimab + GP: 109
(75%)
Placebo + GP: 109
(76%)

Exclusion criteria

Possible benefit from
curative treatments
History of severe
hypersensitivity
reactions to other mAbs
Prior therapy with
Checkpoint Inhibitors
Major surgical procedure
other than for diagnosis
of NPCA within 28 days
History of
hypersensitivity to
gemcitabine or cisplatin
Female patients who are
at pregnancy or lactation

journals.sagepub.com/home/tam

(Continued)

OS, median (95% CI), mo
Toripalimab + GP: NE
Placebo + gemcitabine + cisplatin:
NE
HR = 0.603 (95% CI: 0.364–0.997)
p = 0.0462
PFS, median (95% CI), mo
Toripalimab + GP: 11.7 months (95%
CI: 11.0–NE)
Placebo + GP: 8.0 months (95% CI:
7.0–9.5)
HR = 0.52 (95% CI: 0.36–0.74)
Two-sided p = 0.0003
ORR, % (95% CI)
Toripalimab + GP: 77.4% (95% CI:
69.8–83.9)
Placebo + gemcitabine + cisplatin:
66.4% (95% CI: 58.1–74.1)
p = 0.04*
DCR (CR + PR + SD), % (95% CI)
Toripalimab + GP: 87.7% (95% CI:
81.2–92.5)
Placebo + gemcitabine + cisplatin:
79.7% (95% CI: 72.2–86.0)
p = 0.0694*
DOR, median (range), mo
Toripalimab + GP: 10.0 months (95%
CI: 8.8–NE)
Placebo + GP: 5.7 months (95% CI:
5.4–6.8)
p < 0.0001*

DCR (CR + PR + SD), % (95% CI)
Spartalizumab: 42.7% (95% CI,
31.8–54.1)
Chemotherapy: 70.0% (95% CI,
53.5–83.4)
p = 0.0027*
DOR, median (range), mo
Spartalizumab: 10.2 months (95% CI,
7.4–NE)
Chemotherapy: 5.7 months (95% CI,
3.7–7.4)
p = 0.0370*

Outcomes

ET Polintan, SK Canicula et al.
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Outcomes
OS, median (95% CI), mo
Camrelizumab + GP: not reached
Placebo + GP: 22.6 months (95% CI
19.2–not reached)
HR = 0.67 (95% CI 0.41–1.11)
p = 0.1150*
PFS, median (95% CI), mo
Camrelizumab + GP: 9.7 months (95%
CI 8.3–11.4)
Placebo + GP: 6.9 months (5.9–7.3)
HR = 0.54 (95% CI 0.39–0.76)
One-sided p = 0.0002
ORR, % (95% CI)
Camrelizumab + GP: 87.3% (95% CI
80.5–92.4)
Placebo + GP: 80.6% (95% CI
72.7–87.1)
p = 0.1418*
DCR (CR + PR + SD), % (95% CI)
Camrelizumab + GP: 96.3% (95% CI
91.5–98.8)
Placebo + GP: 94.6% (95% CI
89.1–97.8)
p = 0.5120*
DOR, median (range), mo
Camrelizumab + GP: 8.5 (95% CI
6.9–11.1)
Placebo + GP: 5.6 (95% CI 5.2–6.9)
p = 0.0007*

Treatment arms, dosage and
length of follow-up
Total n = 263
Intervention
Camrelizumab + GP (n = 134);
camrelizumab (200 mg on
day 1) administered IV,
plus gemcitabine (1000 mg/
m² on days 1 and 8) and
cisplatin (80 mg/m² on day
1) IV every 3-week cycle for
four to six cycles, followed
by camrelizumab alone on
day 1 of every 3-week cycle
as maintenance therapy until
radiographic progression,
unacceptable toxicity, start
of new anticancer treatment,
investigator decision, or
withdrawal of consent,
whichever occurred first.
Control: Placebo + GP (n = 129);
placebo administered IV, plus
gemcitabine (1000 mg/m² on
days 1 and 8) and cisplatin
(80 mg/m² on day 1) IV every
3-week cycle for four to six
cycles, followed by placebo on
day 1 of every 3-week cycle
as maintenance therapy until
radiographic progression,
unacceptable toxicity, start
of new anticancer treatment,
investigator decision, or
withdrawal of consent,
whichever occurred first.
Follow-up: Up to 24 months

Baseline
characteristics
Age, years (median,
IQR)
Camrelizumab + GC:
52 (40–58)
Placebo + GC: 49
(40–56)
Sex
Male: 82.9%
Female: 17.1%
Ethnicity
Asian: 100%
Did not screen
patients according to
PD-L1 status

Exclusion criteria
Possible benefit from
curative treatments
Symptomatic CNS
metastases
Other malignant
diseases
Previous checkpoint
inhibitor use
Immunodeficiency
History of non-infectious
pneumonitis
Had active hepatitis B or
C infection
Had active tuberculosis
infection
Had uncontrolled cardiac
disease

value.
CNS, central nervous system; DCR, Disease Control Rate; DOR, Duration of Response; ECOG, Eastern Cooperative Oncology Group; GP, gemcitabine + cisplatin; HBC, hepatitis B virus;
HCV, hepatitis C virus; IQR, interquartile range; irRC, immune-related response criteria; NE, not estimable; NPCA, nasopharyngeal cancer; ORR, Objective Response Rate; OS: Overall
Survival; PFS, Progression-Free Survival; RECIST, response evaluation criteria in solid tumors.

Age ⩾18 and ⩽75 years
Subjects with
histopathological diagnosis
of nasopharyngeal
carcinoma
Primarily metastatic (stage
IVB) or recurrent NPCA
Has not received prior
systemic treatment
Has an ECOG performance
status of 0 or 1
Subject must have a
measurable target lesion
based on RECIST v1.1
Had a life expectancy of at
least 12 weeks

Yang et al.
Camrelizumab versus
placebo in combination
with gemcitabine
and cisplatin as firstline treatment for
R/M nasopharyngeal
carcinoma (CAPTAIN1st): a multicenter,
randomized, double-blind,
phase 3 trial
2021
Phase III, double-blinded,
RCT
China

*Estimated

Inclusion criteria

First author, title, year,
design, location

Table 1. (Continued)
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Figure 3. Progresion-free survival forest plot.

95% CI, 95% confidence interval; IV, inverse variance; SE, standard of error.

Figure 4. Overall survival forest plot.

95% CI, 95% confidence interval; IV, inverse variance; SE, standard of error.

combination subgroup showed an HR of 0.53
[0.41, 0.68] (p < 0.001) (Figure 3).
Overall survival
PD-1 monotherapy revealed an HR of 0.87 [0.67,
1.13] (p = 0.30). The combination subgroup
revealed an HR of 0.64 [0.45, 0.90] (p = 0.01)
(Figure 4).
Discussion
Included PD-1 inhibitors
The studies included in our data synthesis utilized four drugs within the category of PD-1
inhibitors: pembrolizumab, spartalizumab, toripalimab, and camrelizumab. PD-1 inhibitors are
a form of targeted therapy that blocks PD-1/
journals.sagepub.com/home/tam

PD-L1 interaction using humanized monoclonal
IgG4 kappa anti-PD1 antibodies. Because of this,
they have no cytotoxic effects unlike conventional
chemotherapy. Pembrolizumab is the first FDA
approved PD-1 inhibitor in the US on 4
September 2014.26 It is often used in the treatment of metastatic or advanced unresectable melanoma and PD-1 positive NSCLC.27–29
Spartalizumab is a drug that is currently not
approved by the FDA for use outside of clinical
trials with a phase 1 dose escalation study finding
spartalizumab being well tolerated in patients
with advanced solid tumors.30 However unlike
pembrolizumab, spartalizumab is usually associated with only a non-significant benefit in unresectable metastatic melanoma.31 Toripalimab was
approved for use in China in December 2018 for
use in the treatment of unresectable or metastatic
melanoma that has failed previous systemic
9
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therapy and is generally well tolerated in Chinese
patients with advanced malignancies.32,33 Cam
relizumab was a drug conditionally approved for
the treatment of relapsed or refractory classical
Hodgkin lymphoma who have received at least
two previous systemic chemotherapies in May
2019 by China.34 A more detailed comparison of
the included drugs could be seen in supplemental
Table 2.
Monotherapy as second-line
Results from our data synthesis of the monotherapy subgroup showed that PD-1 inhibitors exhibit
no significant benefits with OS, DOR, and total
AE. Significantly worse outcomes were seen on
PFS and DCR while a non-significant result was
seen in ORR. However, PD-1 monotherapy had
significantly less rates of anemia, neutropenia,
and diarrhea compared to chemotherapy alone.
Which is congruent with the less cytotoxic effects
of PD-1 inhibitors in contrast to platinum-based
chemotherapy. When compared to the phase III
trial by Cohen et al. on platinum pre-treated R/M
squamous cell HNC samples, those with
Combined Positive Score (CPS) ⩾1 showed a
significant OS benefit (0.74 [0.58, 0.93];
p = 0.0049).13 While PFS, ORR, and AEs showed
no significant difference between treatment and
control arms. The difference in results between
the pooled NPCA and HNC outcomes with PD-1
monotherapy tells us that the physiologic and
genetic differences driving HNC do not equate to
that of the NPCA population as the study by
Cohen et al. analyzed R/M squamous cell HNC
of the oropharynx, hypopharynx, and larynx.
Supporting this is the fact that there is a notable
predominance of Caucasians in the HNC samples by Cohen et al. which is in contrast to the
majority Asian population from the monotherapy
subgroup’s NPCA samples. This highlights the
necessity of differentiating NPCA from other
HNCs. Additionally, Cohen et al. analyzed those
with CPS ⩾1 separately from those with CPS <1
whereas Chan et al. and Even et al. did not separate their analysis by CPS score. There is also a
difference in the number of participants analyzed
as Cohen et al. (n = 387) outnumbers the monotherapy subgroup (n = 276) in CPS ⩾1 participants. These differences could be the reason as to
why NPCA appears to be responding worse compared to other HNC. Overall, it appears that
PD-1 inhibitor monotherapy is not superior to
chemotherapy in the platinum pre-treated R/M
NPCA in an Asian population.
10
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Combination therapy as first-line
The combination subgroup showed a consistent
benefit in all five outcomes with no significant difference noted in the risk of total AEs. In comparison, a recently published RCT abstract by Zhang
et al. comparing tislelizumab + chemotherapy versus placebo + chemotherapy on 263 R/M NPCA
patients undergoing first-line therapy is similar to
our combination subgroup’s population. Zhang
et al.35 found that an HR of 0.60 [0.35, 1.01] for
OS, 0.50 [0.37, 0.68] for PFS, and 0.38 [0.25,
0.58] for PFS post-tislelizumab monotherapy
after noted disease progression. The results from
this study supports our findings despite the nonsignificant benefit seen in OS for the tislelizumab
arm. Similarly, a meta-analysis using nine RCTs
by Petrelli et al. on the usage of immune checkpoint inhibitors (ICI) on NSCLC shows similar
results to our findings where OS, PFS, and ORR
were found to be significantly in favor of
ICI + chemotherapy compared to chemotherapy
alone.36 In contrast to our results however, Grade
3–5 AEs were noted to be significantly more frequent in the ICI arm. This could be explained by
the usage of CTLA-4 and PD-L1 inhibitors
where it was found that those patients given ipilimumab, a CTLA-4 inhibitor, or atezolizumab, a
PD-L1 inhibitor, expressed significantly higher
rates of AEs. It is also notable that Petrelli et al.
showed a moderate to high amount of heterogeneity on all parameters measured (I2 = 48–82%)
which implies inconsistency in the effects of the
pooled studies. Interestingly, Petrelli et al. also
found that the magnitude of benefit was low in
those with squamous histology, PD-L1 expression <50%, liver metastases, female sex, and
never-smoking history. Making investigations
into these subpopulations of patients is worth
looking into for NPCA as well. Nonetheless, our
findings suggest a general trend of improved outcomes with PD-1 inhibitor + chemotherapy over
chemotherapy alone as a treatment modality in
the first-line setting of R/M NPCA patients.
Recommendations and caveats
Although other published studies with PD-1
inhibitors in the HNC population show promising results, there is currently a severe lack of PD-1
or PD-L1 checkpoint inhibitor RCT studies on
the NPCA population. Our meta-analysis suggests a very optimistic outcome with the use of
combined PD-1 inhibitor + chemotherapy as a
treatment modality in R/M NPCA as first-line
treatment. Thus, we recommend more clinical
journals.sagepub.com/home/tam
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trials comparing this modality with standard of
care to definitively conclude the existence of
superiority which could potentially change the
future management of this disease. Currently,
there are three phase 3 trials (NCT04458909,
NCT03924986, and NCT04974398) and one
phase 1 trial (NCT04282070) ongoing that compares combined chemotherapy and PD-1 inhibitors with standard chemotherapy alone in R/M
NPCA patients.37 Another meta-analysis could
be done once more RCTs on this subject are
available for pooling.
According to a cost-effectiveness analysis by Zhu
et al. toripalimab + chemotherapy associated with
an incremental cost-effectiveness ratios (ICERs)
of $19,726 per quality-adjusted life-years (QALY)
while camrelizumab + chemotherapy was associated with $20,438 per QALY.38 In comparison,
standard chemotherapy is estimated to have a
total cost of $26,680 compared to $48,525 and
$46,293 for toripalimab and camrelizumab +
chemotherapy respectively. Despite this substantial increase in cost, the same study goes on to say
that willingness-to-pay (WTP) for Chinese citizens was found to be at $35,673 per QALY using
a Markov model. Therefore, due to ICER being
lower than WTP, it would appear that cost-effectiveness for PD-1 inhibitor therapy is still met
despite the higher total cost of a PD-1 inhibitor + chemotherapy regimen for at least the
Chinese population.
An interesting result from Even et al.25 is their
finding of a negative correlation between IFNgamma, TIM-3, and LAG-3 status to spartalizumab response. Additionally, Huang et al. found
that PD-1 inhibitors and PD-L1 inhibitors have
differing effectiveness in HNC patients, as only a
non-statistically significant result in PD-L1 inhibitor + chemotherapy combination was seen [PD-1
inhibitors (RR 1.91 [1.42, 2.56]); PD-L1 inhibitors (RR of 1.54 [0.81, 2.94])].39 In comparison,
a statistically significant benefit with PD-1 inhibitor + chemotherapy was seen from the clinical trials included in this meta-analysis as well as the
subgroup analysis done by Huang et al. themselves. Therefore, the difference in efficacy
between PD-L1 versus PD-1 inhibitors as well as
further studies on IFN-gamma, TIM-3, and
LAG-3 positive patients’ response to PD-1 inhibitors would be worthwhile avenues to further
investigate.

journals.sagepub.com/home/tam

Limitations
Only four eligible studies were included in our
pooled data synthesis. The addition of a phase II
trial with a smaller sample size decreases the total
power of our pooled analysis. For similar reasons,
the subjects may have also been given suboptimal
drug dosing which could have led to the non-significant results seen.40 The two studies included
in the monotherapy subgroup were open-label,
which predisposed both studies to performance
and detection bias, and did not meet their primary endpoints. Of the studies included in the
combination subgroup, the CAPTAIN-1st trial
by Yang et al. and the JUPITER-02 trial by Mai
et al. had the additional limitation of comparing
their maintenance phase PD-1 inhibitor therapy
with placebo instead of maintenance chemotherapy.23,24 Notably however, this is still in line with
current guidelines as maintenance chemotherapy
is currently not recommended due to being associated with higher risks for AEs.41 Approximately,
only 60% are able to finish their planned maintenance chemotherapy and nearly 50% require
dose reduction.41 It is also worth noting that all
studies were financed by pharmaceutical companies, risking sponsorship bias especially for those
under an open-label design. However, third-party
review committees were utilized by all included
studies in an attempt to mitigate this effect.
In three out of four studies, PD-L1 was the only
biomarker measured while Yang et al. didn’t
measure for PD-L1 status at all. There was also
no measurement of outcomes by PD-L1 status,
resulting in our data synthesis being unable to do
a subgroup analysis response per PD-L1 status.
Similarly, Even et al. was the only one who measured for IFN-gamma, TIM-3, and LAG-3 status
which appeared to have shown a negative correlation for spartalizumab response in platinumpretreated patients. However, their small sample
size limits the validity of this finding and more
studies are needed to verify this result. Another
issue concerns the study by Chan et al. where the
abstract and results have been published but has
not yet undergone full peer-review at the time of
this paper’s writing. Additionally, all of the
included studies had a majority EBV-positive
patient sample. This indicates that the findings
from our analysis is only applicable to EBVpositive patients. Lacking representation of EBVnegative patients, a relevant population of NPCA
patients in non-endemic regions outside of Asia.
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Finally, all studies included were RCTs which
represent the best level of evidence available at
the time of this article’s writing. However, the
presence of confounders leads to a downrating in
validity based on the issues raised by all the aforementioned biases. Despite this, the consistent
benefit seen in combination PD-1 inhibitors + chemotherapy subgroup in all five outcomes and lack of significant toxicity even after
prolonged exposure in the PD-1 inhibitor arm’s
maintenance phase leads us to believe our present
evidence warrants at least a GRADE certainty
rating of moderate for all outcomes measured.42
Meanwhile the monotherapy subgroup’s outcomes could be given a low to moderate GRADE
certainty rating due to the inherent limitations
mentioned before.42
Conclusion
In R/M NPCA, both PD-1 inhibitor monotherapy and combination therapy are comparable in
safety to chemotherapy alone. However, PD-1
inhibitor monotherapy in platinum pre-treated
R/M NPCA is not superior to chemotherapy
alone as second-line treatment. Conversely,
combination PD-1 inhibitor + chemotherapy as
first-line treatment of R/M NPCA appears to be
superior to chemotherapy alone, thereby implying a potential benefit with the use of PD-1
inhibitors + chemotherapy with maintenance
PD-1 inhibitors as first-line in R/M NPCA as
opposed to standard chemotherapy alone. More
evidence from RCTs are needed to further validate the role of PD-1 inhibitors in the management of NPCA.
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